MARKET

LCTX

LCTX

Lineage Cell Therapeutics Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

2.450
+0.030
+1.24%
After Hours: 2.480 +0.03 +1.22% 17:41 09/22 EDT
OPEN
2.400
PREV CLOSE
2.420
HIGH
2.500
LOW
2.390
VOLUME
507.27K
TURNOVER
--
52 WEEK HIGH
3.132
52 WEEK LOW
0.8600
MARKET CAP
410.28M
P/E (TTM)
-31.9843
1D
5D
1M
3M
1Y
5Y
Lineage to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021
CARLSBAD, Calif., September 20, 2021--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, the Company’s C...
Business Wire · 2d ago
38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares jumped 177.2% to $19.60 after the company announced the United States Patent and Trademark Office has issued a notice of allowance for claims related to the company's platform technology.
Benzinga · 09/15 16:01
Lineage Cell Therapeutics Reports Updated Interim Results From Ongoing, 24-Patient Phase 1/2a Trial Of Its OpRegen
First Reported Case of Retinal Tissue Restoration Showed Zero Growth of Atrophy at 33 Months Second Case of Retinal Tissue Restoration Exhibited a 10% Reduction in Atrophy Size at 8 Months Third Case of Retinal
Benzinga · 09/15 13:04
Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy
CARLSBAD, Calif., September 15, 2021--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported updated interim results from its ongoi...
Business Wire · 09/15 13:00
Lineage Cell Says Interim Data Shows OpRegen Can Provide Improvements in Patients With Dry Age-Related Macular Degeneration
MT Newswires · 09/15 11:28
Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
CARLSBAD, Calif., September 13, 2021--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, reported today that updated interim results from a Ph...
Business Wire · 09/13 12:00
Lineage Announces Appointment of General Counsel
CARLSBAD, Calif., September 01, 2021--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has appointed George A. Samue...
Business Wire · 09/01 12:00
Noble Capital Markets Initiates Coverage On Lineage Cell Therapeutics with Outperform Rating, Announces Price Target of $8
Noble Capital Markets analyst Robert LeBoyer initiates coverage on Lineage Cell Therapeutics (AMEX:LCTX) with a Outperform rating and announces Price Target of $8.
Benzinga · 08/19 15:55
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LCTX. Analyze the recent business situations of Lineage Cell Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LCTX stock price target is 6.40 with a high estimate of 8.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 118
Institutional Holdings: 66.40M
% Owned: 39.65%
Shares Outstanding: 167.46M
TypeInstitutionsShares
Increased
29
919.96K
New
11
1.63M
Decreased
26
988.89K
Sold Out
19
1.29M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.30%
Pharmaceuticals & Medical Research
-0.11%
Key Executives
Chairman/Director
Alfred Kingsley
Chief Executive Officer/Director
Brian Culley
Chief Financial Officer
Kevin Cook
Finance Director/Controller
Alexandra Hernandez
Senior Vice President
Gary Hogge
General Counsel/Secretary
George Samuel
Independent Director
Dipti Amin
Independent Director
Deborah Andrews
Independent Director
Don Bailey
Independent Director
Neal Bradsher
Independent Director
Anula Jayasuriya
Independent Director
Michael Mulroy
Independent Director
Angus Russell
No Data
  • All
  • Financials
  • Insiders
More
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing cell therapies for unmet medical needs. It is focused on developing therapies for degenerative retinal diseases, neurological conditions associated with demyelination and aiding the body in detecting and combating cancer. Specifically, it is testing therapies to treat dry age-related macular degeneration, spinal cord injuries and non-small cell lung cancer. It has three allogeneic cell therapy programs: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium cell replacement therapy being developed for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy. OPC1 is an oligodendrocyte progenitor cell therapy that is being developed for acute spinal cord injuries (SCI). VAC2 is a cancer immunotherapy of antigen-presenting dendritic cells that is being developed for non-small cell lung cancer.

Webull offers kinds of Lineage Cell Therapeutics Inc stock information, including AMEX:LCTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LCTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LCTX stock methods without spending real money on the virtual paper trading platform.